Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Citi
Baxter
Cantor Fitzgerald
Argus Health
Mallinckrodt
McKinsey
AstraZeneca
Boehringer Ingelheim

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,259,539

« Back to Dashboard

Which drugs does patent 9,259,539 protect, and when does it expire?

Patent 9,259,539 protects AUVI-Q and is included in one NDA.

This patent has one hundred patent family members in fourteen countries.
Summary for Patent: 9,259,539
Title:Devices, systems and methods for medicament delivery
Abstract: An apparatus includes a label configured to be coupled to a medicament delivery device. The label includes a first surface and a second surface. The first surface is configured to be coupled to an outer surface of the medicament delivery device. The second surface includes a textual indicia. The label further includes an electronic circuit system configured to output an electronic signal.
Inventor(s): Edwards; Eric S. (Moseley, VA), Edwards; Evan T. (Charlottesville, VA), Licata; Mark J. (Doswwell, VA), Meyers; Paul F. (Fishers, IN), Weinzierl; David A. (Andover, MN)
Assignee: kaleo, Inc. (Richmond, VA)
Application Number:14/470,165
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 9,259,539

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-003 Nov 17, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-002 Aug 10, 2012 BX RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-001 Aug 10, 2012 BX RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,259,539

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,648,483 Devices, systems and methods for medicament delivery ➤ Try a Free Trial
7,731,686 Devices, systems and methods for medicament delivery ➤ Try a Free Trial
8,361,026 Apparatus and methods for self-administration of vaccines and other medicaments ➤ Try a Free Trial
7,731,690 Devices, systems and methods for medicament delivery ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,259,539

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004325202 ➤ Try a Free Trial
Australia 2006210865 ➤ Try a Free Trial
Australia 2007245139 ➤ Try a Free Trial
Australia 2009200841 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Express Scripts
Chinese Patent Office
Harvard Business School
Accenture
Fuji
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.